Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses recent updates on the use of CAR-T therapy in multiple myeloma and the value of these agents. Prof. Mohty first highlights the importance of having two CAR-T cells approved in the relapsed/refractory (R/R) setting, namely ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel). Following this, Prof. Mohty discusses important clinical trials in this space, including the KarMMa-3 trial (NCT03651128) and the CARTITUDE-4 trial (NCT04181827), and concludes by highlighting the value of novel GPRC5D and FcRH5-targeted agents. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть